Progressive neurodegeneration and decline of cognitive functions are major hallmarks of Alzheimer disease (AD). Neurodegeneration in AD correlates with dysfunction of diverse signal transduction mechanisms, such as the G-protein-stimulated phosphoinositide hydrolysis mediated by G␣ q/11 . We report here that impaired G␣ q/11 -stimulated signaling in brains of AD patients and mice correlated with the appearance of crosslinked oligomeric angiotensin II AT 2 receptors sequestering G␣ q/11 . Amyloid  (A) was causal to AT 2 oligomerization, because cerebral microinjection of A triggered AT 2 oligomerization in the hippocampus of mice in a dose-dependent manner. A induced AT 2 oligomerization by a two-step process of oxidative and transglutaminase-dependent cross-linking. The induction of AT 2 oligomers in a transgenic mouse model with AD-like symptoms was associated with G␣ q/11 dysfunction and enhanced neurodegeneration. Vice versa, stereotactic inhibition of AT 2 oligomers by RNA interference prevented the impairment of G␣ q/11 and delayed Tau phosphorylation. Thus, A induces the formation of cross-linked AT 2 oligomers that contribute to the dysfunction of G␣ q/11 in an animal model of Alzheimer disease.
Alzheimer disease (AD)2 is a protein aggregation disease that is characterized by profound neuropathological changes in the brain, including neurodegeneration, neurofibrillary tangles, and the accumulation of fibrillar -amyloid (A) in extracellular senile plaques. Although some neuropathological features of AD, such as tangles and plaques, are also detected in brains of elderly people without major symptoms of dementia (1), neurodegeneration and neuronal loss of AD patients are associated with the major AD symptoms of memory impairment and dementia (2, 3). Neurodegeneration in AD is accompanied by dysfunction of diverse signal transduction mechanisms, such as the G-protein-stimulated phosphoinositide hydrolysis mediated by G␣ q/11 (4 -8). G␣ q/11 -stimulated signal transduction pathways are important for neuronal communication, synaptic plasticity, and neuronal survival (9, 10). Therefore, it is likely that the G␣ q/11 signaling defect of AD patients plays a role in the disease process leading to neurodegeneration and dementia. In agreement with this notion, G-protein dysfunction is directly associated with disease severity of AD patients (8).Further insight into the pathological role of the G-protein dysfunction of AD patients is lacking, because the underlying mechanism is barely understood. Several observations point to a specific defect at the level of G␣ q/11 : (i) protein levels of G␣ q/11 are not changed (7); (ii) downstream receptor/G-protein-independent phosphoinositide hydrolysis is intact (7); and (iii) receptor-mediated activation of other G-proteins, such as the G␣ i/o proteins, is not affected (5). In view of a putative role in the pathogenesis, we investigated the mechanism accounting for defective G␣ q/11 activation in AD.G␣ q/11 activation is under control of specific receptors. Although mo...